Embozene Microspheres vs. Embosphere Microspheres for uterine fibroid embolization
This is a multicenter prospective randomized trial designed to evaluate the outcomes after the UFE procedure when performed with either Embozene Microspheres (Boston Scientific Corporation) or Embosphere Microspheres (Merit Medical Systems). The outcomes being evaluated include the degree of improvement in both symptom severity and health-related quality of life (as measured on the UFS-QOL questionnaire) as well as the rate of fibroid infarction (as seen on contrast-enhanced MRI).
Y90 Resin Microspheres Data Collection in Unresectable Liver Cancer (the RESIN Study)
This study is a national registry that evaluating the patient selection, technique, outcomes, and complication after radioembolization performed with yttrium-90 microspheres (Sirtex Medical, Inc.) as a treatment for primary or metastatic cancer of the liver.
Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (the PRESERVE Trial)
The PRESERVE Trial is the first large-scale, multi-specialty, prospective clinical study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States. It is sponsored by IVC Filter Study Group Foundation, which is a joint collaboration between the Society of Interventional Radiology (SIR) and the Society for Vascular Surgery (SVS). For more information, please visit the PRESERVE Trial website.